2022
Notice of Adjustment to 340B Price for Vertex Pharmaceuticals' Trikafta® (PDF - 105 KB)
NovoNordisk Notice of Refunds to 340B Covered Entities (PDF - 77 KB)
BMS Notice to Covered Entities of Refunds to 340B Covered Entities (PDF - 146 KB)
Notice of Partial Refund Ipsen's Somatuline® Depot (PDF - 140 KB)
GSK Notice of Refunds to 340B Covered Entities (PDF - 386 KB)
Exelan Notice of Refunds to 340B Covered Entities (PDF - 123 KB)
BioMarin Notice of Refunds to 340B Covered Entities Q4 2020 - Q1 2021 (PDF - 266 KB)
Notification of Supply Allocation: Vidaza (azacitidine) (PDF - 148 KB)
Johnson and Johnson Notice Regarding Refunds to 340B Covered Entities (PDF - 75 KB)
Mytesi Notice of Distribution Network (PDF - 463 KB)
Notification of Global Shortage of Actemra IV (tocilizumab) (PDF - 67 KB)
BioMarin - Notice of Refund to 340B Covered Entities Q1 2019 – Q4 2020 (PDF - 27 KB)
Notice of Limited Distribution for Pegcetacoplan (PDF - 138 KB)
Novartis Notice of 340B Price Adjustment (PDF - 25 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc (PDF - 105 KB)
Updated Notice Regarding Limited Distribution Plan for AYVAKIT (avapritinib) (PDF - 520 KB)
Purdue Notification to Covered Entities of Price Recalculations (PDF - 191 KB)
SpecGX LLC (Mallinckrodt) Notice to Covered Entities of Price Recalculations (PDF - 511 KB)
Verity Notice to Covered Entities of Continuation of Limited Distribution Plan for TRELSTAR (PDF - 140 KB)
Chartwell RX LLC Notice to Covered Entities of Price Recalculations (PDF - 106 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Xellia Pharmaceuticals (US) LLC (PDF - 127 KB)
Takeda Notification of Updated Limited Distribution Plan for Iclusig (PDF - 159 KB)
Civica Notice to Covered Entities of Price Recalculation (PDF - 121 KB)
340B Distribution Notice for Nulibry™ (PDF - 146 KB)
Pharmaceutical Associates Inc. Notice to Covered Entities of Price Recalculations (PDF - 158 KB)
Update to 2021 Distribution Plan for Bausch Health Branded Rx NDCs – Renewed Availability through Amerisource Bergen (PDF - 200 KB)
Esperion Notice to Covered Entities of Price Recalculations (PDF - 102 KB)
GSK Notice to Covered Entities of Price Recalculations (PDF - 69 KB)
Notice Regarding Adjustment of 340B Ceiling Prices for Certain Products of Hikma Pharmaceuticals USA, Inc. (PDF - 245 KB)
Beach Products Inc. Labeler 00486 Recalculation K Phos (PDF - 79 KB)
eTon Pharmaceuticals Notice of Limited Distribution Plan for ALKINDI SPRINKLE (PDF - 139 KB)
Notice Regarding Recalculated 340B Covered Entities for Certain Products of Westminster Pharmaceuticals (PDF - 222 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma Inc. (PDF - 694 KB)
Purdue Notice to Covered Entities of Price Changes for Labeler 59011/67618 (PDF - 511 KB)
Notice Regarding Limited Distribution Plan for Ketorolac Tromethamine Nasal Spray (Sprix® Nasal Spray) (PDF - 420 KB)
UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use) (PDF - 135 KB)
REVISED Notice to 340B Covered Entities Regarding BALVERSA® Limited Distribution Plan (PDF - 97 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Novo Nordisk Inc. (PDF - 116 KB)
Limited Distribution Notice for EVRYSDI (risdiplam) (PDF - 50 KB)
MorphoSys Notice to 340B Covered Entities Regarding MONJUVI® (tafasitamab-cxix) for Injection for Intravenous Use (PDF - 131 KB)
Notice Regarding Recalculated 340B Ceiling Prices for Chiesi USA, Inc. Products Impacted for the Time Period 3Q2016 – 1Q2020 (PDF - 623 KB)
Notice to 340B Covered Entities Regarding Uplizna™ (inebilizumab-cdon) Limited Distribution Network (PDF - 358 KB)
Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc. (PDF - 127 KB)
Notice Regarding Offer of Refunds to 340B Covered Entities for Purchases of NuvaRing® (PDF - 146 KB)
Notice to 340B Covered Entities: Zestril® Limited Distribution (PDF - 110 KB)
Sunovion Pharmaceuticals, Inc. Limited Distribution Network for KYNMOBI™ (PDF - 77 KB)
Notice to 340B Covered Entities Regarding PALYNZIQ™ (PDF - 62 KB)
Notice on Otezla Replacement NDCs (PDF - 93 KB)
Taiho Oncology Inc. Notice of Limited Distribution Network (PDF - 130 KB)
Notice of Price Adjustment to 340B Covered Entities That Purchased ZEVALIN® from Q3 2009 through Q2 2020 (PDF - 91 KB)
Limited Distribution Notice for Opsumit, Tracleer, Uptravi, Veletri, Ventavis, and Zavesca
(PDF - 138 KB)
Limited Distribution Plan Notice for Cialis® (tadalafil) Erectile Dysfunction NDCs (PDF - 111 KB)
Notice Regarding Limited Distribution Network for Nourianz (Istradefylline) (PDF - 64 KB)
Alternative Distribution Plan for Certain Bausch Health NDCs and Notice of Covered Entity Refunds (PDF - 126 KB)
Incyte Limited Distribution Network for Pemazyre (PDF - 33 KB)
Incyte Updated Defined Distribution Network for Jakafi (PDF - 40 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Lupin Pharmaceuticals Inc. (PDF - 519 KB)
Notice of Distribution Model for Qinlock™ (PDF - 328 KB)
UPDATED NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG BCG LIVE (for intravesical use) (PDF - 181 KB)
Notice of Price Adjustment to PHS Covered Entities (PDF - 34 KB)
Removal of Program Astagraf Limited Distribution Plan (PDF - 229 KB)
Purdue Pharma L.P. and its subsidiaries Aviro Health L.P. and Adlon Therapeutics L.P. Notice of adjusted 340B Prices (PDF - 270 KB)
Bayer Healthcare Limited Distribution Plan for Adempas (PDF - 49)
Limited Distribution Network for DOPTELET® (avatrombopag) Updated 2020 (PDF - 554 KB)
Vertex Pharmaceuticals Inc. Notice of Limited Distribution Plan (PDF - 132 KB)
Notice for Resticted Distribution Network for Sublocade (PDF - 158 KB)
Exelixis Notice of Distribution Model for Cabometyx (PDF - 154 KB)
Notice Regarding Repatha Replacement (PDF - 80 KB)
Updated Notice of Distribution Model for Cometriq (PDF - 132 KB)
Notice of Change in Distribution Model for TYMLOS® (PDF - 545 KB)
Notice Regarding Recalculated 340B ceiling prices for Apotex Corp (PDF - 15 KB)
Distribution Plan for certain generic products for Bausch Health (PDF - 111 KB)
Limited Distribution Notice for NUPLAZID® (pimavanserin) Tablets and Capsules (PDF - 67 KB)
Notice Regarding Recalculated 340B Ceiling Prices for Certain Products of Astellas Pharma US, Inc. (PDF - 167 KB)
Notice of Change in Distribution Model for Kitabis™ Pak (NDC 24492-850-56) (PDF - 347 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. and Avrio Health L.P. (PDF - 256 KB)
Notice to 340B Covered Entities Regarding Replacement NDCS For Enbrel® (PDF - 95 KB)
Notice to 340B Covered Entities That Purchased Xspire Products (PDF - 135 KB)
340B Limited Distribution Notice for Corlanor® (ivabradine) Oral Solution 5 mg (NDC 55513-0813-28) (PDF - 82 KB)
Updated Notice to 340B Covered Entities Regarding Panzyga Immune Globulin Intravenous (Human) ifas 10% Liquid Preparation (PDF - 73 KB )
Notice to 340B Covered Entities Regarding Cutaquig Immune Globulin Subcutaneous (Human)-hipp 16.5% Solution (PDF - 113 KB)
Notice of Change in Distribution Model for Adrenalin and Vasostrict (PDF - 339 KB)
Notice to 340B Covered Entities Regarding Calcium Acetate (Generic) Capsules (PDF - 86 KB)
Updated 340B Limited Distribution Notice for Xermelo (PDF - 147 KB)
340B Notice Regarding Updated Limited Distribution Plan for Nulojix (belatacept) (PDF - 132 KB)
Daiichi Sankyo Notice to 340B Covered Entities Regarding Turalio™ (PDF - 38 KB)
Notice to 340B Covered Entities Regarding GAMMAKED [Immune Globulin Injection (Human), 10% Caprylate/Chromatography Purified] (PDF - 79 KB)
Notice to 340B Covered Entities Related to Axumin™ (NDC # 69932-0001-01) (PDF - 107 KB)
Notice to Covered Entities Regarding Balversa Limited Distribution Plan (PDF - 68 KB)
340B Limited Distribution Notice for OXERVATE (NDC 71981-0020-01) (PDF - 152 KB)
Notice Regarding Recalculated 340B Price for Amphastar Pharmaceuticals, Inc. (PDF - 84 KB)
Notice Regarding Recalculated 340B Ceiling Prices for The Medicines Company Products (PDF - 88 KB)
Notice Regarding Adjustment of 340B Prices for Purdue Pharma L.P. (PDF - 272 KB)
Millennium Pharmaceuticals Notice Regarding Adjustment of 340B Prices for Velcade (PDF - 44 KB)
Vifor Mircera Notice of End of Limited Distribution Plan (PDF - 273 KB)
Catalyst FIRDAPSE® (amifampridine) tablets Notice Regarding Limited Distribution Plan (PDF - 205 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Kedrion Biopharma, Inc. (PDF - 362 KB)
Notice Regarding Recalculated 340B Prices for Sebela Products (PDF - 230 KB)
Notice Regarding Adjustment of 340B Prices for Select Products of Purdue Pharma L.P. (PDF - 106 KB)
NOTIFICATION OF SUPPLY ALLOCATION: TICE® BCG (BCG LIVE for intravesical use) (PDF - 54 KB)
Array Biopharma Notice of Defined Distribution Network for BRAFTOVl® (encorafenib) and MEKTOVI* (binimetinib) (PDF - 94 KB)
Insmed Limited Distribution Plan for ARIKAYCE (PDF - 52 KB)
Biovertiv Replenishment Notice to Covered Entities for Alprolix and Elocate) (PDF - 341 KB)
Akorn Notice to covered entities potential overcharge Methylene Blue 1% 10ml (PDF - 648 KB)
Agios TIBSOVO® Limited Distribution Plan (PDF - 36 KB)
Recalculated 340B Ceiling Prices for Lilly Products (PDF - 72 KB)
Valeant potential overcharge letter labeler 16781 NDC's (PDF - 205 KB)
Notice Regarding Recalculated 340B Ceiling Prices for Genentech Product (PDF - 57 KB)
Shire 340B Ceiling Price Recalculation Notice (PDF - 65 KB)
Almatica Pharma-Tenormin Limited Distribution Plan (PDF - 137 KB)
Johnson and Johnson Healthcare Systems Inc. Notice of 340B Pricing via Cardinal Health Specialty Pharmaceutical Distribution (PDF - 95 KB)
Johnson and Johnson Healthcare Systems Inc. Notice regarding 340B Ceiling Prices for 1Q2017 (PDF - 137 KB)
Neurocrine Biosciences 340B Limited Distribution plan for INGREZZA (PDF - 95 KB)
Notice Regarding Pfizer Defined Oncology Distribution Network (PDF - 99KB)
Notice Regarding 340B Pricing for Millennium Pharmaceuticals VELCADE (PDF - 40 KB)
Notice Regarding 340B Pricing for BiCNU (PDF - 76 KB)
UPDATE Notice to 340B Covered Entities Regarding Baxalta's VONVENDI (PDF - 129 KB)
340B Notice Regarding Limited Distribution Plan for Imbruvica (ibrutinib) (PDF - 87 KB)
Notice to 340B Covered Entities Regarding 340B Ceiling Prices for Ascend Products (PDF - 114 KB)
Notice to 340B Covered Entities Regarding Recalculated 340B Ceiling Price for Amgen Products and Issuance of Credits (PDF - 48 KB)
2015: Notice Regarding Limited Distribution Network for Reylimid, Pomalyst and Thalomid (PDF - 95 KB)
2014: Bayer Limited Distribution System for Betaseron (PDF - 66 KB)
2013: Bayer Skyla Letter (PDF - 117 KB) 05/31/2013
2011: Yaz® Limited Distribution System (PDF - 21 KB) 03/30/2011
2009: Limitations on Sales of Venofer® (PDF - 18 KB) 10/29/2009
2008: Yasmin® Limited Distribution System (PDF - 21 KB) 09/30/2008
Accessibility
If you use assistive technology, you may not be able to fully access information in these files. For assistance, please email 340B-Communication@hrsa.gov.
